Improving therapy for patients with aggressive lymphoma.

The outcome for patients with diffuse large B-cell lymphomas improved dramatically in the last decade, and the opportunity for improving therapy for patients with peripheral T-cell lymphoma exists as we begin to study specific subtypes of the disease. It is entirely possible that patients with different genetic subtypes of diffuse large B-cell lymphoma will eventually require different treatments, and the same will be true for patients with subtypes of peripheral T-cell lymphoma. These possibilities will be the focus of clinical investigation over the next decade.